Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Terns Granted US Fast Track Status for NASH Candidate

publication date: Oct 30, 2019

Terns Pharma, a Shanghai-San Francisco biopharma, announced that TERN-101, a farnesoid X receptor (FXR) agonist, was granted Fast Track Designation by the US FDA to treat NASH. In 2018, Terns in-licensed global rights to TERN-1, together with a second NASH candidate, from Eli Lilly. Lilly Asia Ventures also invested $30 million in Tern at the same time. In preclinical testing, TERN-101 reduced liver steatosis, inflammation, ballooning and fibrosis in a NASH model. Phase I pharmacokinetics were consistent with once-daily dosing. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital